JP2017509713A - アルミニウム塩に吸着させたワクチンの免疫賦活能を強化するための方法 - Google Patents

アルミニウム塩に吸着させたワクチンの免疫賦活能を強化するための方法 Download PDF

Info

Publication number
JP2017509713A
JP2017509713A JP2017502571A JP2017502571A JP2017509713A JP 2017509713 A JP2017509713 A JP 2017509713A JP 2017502571 A JP2017502571 A JP 2017502571A JP 2017502571 A JP2017502571 A JP 2017502571A JP 2017509713 A JP2017509713 A JP 2017509713A
Authority
JP
Japan
Prior art keywords
adsorbed
aluminum
immunogen
aluminum salt
mpla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017502571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509713A5 (enExample
Inventor
アルビング，カール，アール．
キム，ジェローム，エイチ．
ラオ，マンガラ
Original Assignee
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー, ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー filed Critical ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー
Publication of JP2017509713A publication Critical patent/JP2017509713A/ja
Publication of JP2017509713A5 publication Critical patent/JP2017509713A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16271—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2017502571A 2014-03-25 2014-07-09 アルミニウム塩に吸着させたワクチンの免疫賦活能を強化するための方法 Pending JP2017509713A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461969905P 2014-03-25 2014-03-25
US61/969,905 2014-03-25
PCT/US2014/045940 WO2015147899A1 (en) 2014-03-25 2014-07-09 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines

Publications (2)

Publication Number Publication Date
JP2017509713A true JP2017509713A (ja) 2017-04-06
JP2017509713A5 JP2017509713A5 (enExample) 2017-08-17

Family

ID=51302762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502571A Pending JP2017509713A (ja) 2014-03-25 2014-07-09 アルミニウム塩に吸着させたワクチンの免疫賦活能を強化するための方法

Country Status (12)

Country Link
US (1) US20170165358A1 (enExample)
EP (1) EP3122379A1 (enExample)
JP (1) JP2017509713A (enExample)
KR (1) KR20170016315A (enExample)
CN (1) CN106535929A (enExample)
AU (1) AU2014388299A1 (enExample)
BR (1) BR112016021692A2 (enExample)
CA (1) CA2943050A1 (enExample)
MX (1) MX2016012166A (enExample)
RU (1) RU2016141621A (enExample)
SG (2) SG10201808312YA (enExample)
WO (1) WO2015147899A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020090445A (ja) * 2018-12-04 2020-06-11 国立大学法人大阪大学 免疫賦活剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US20230134067A1 (en) * 2020-07-22 2023-05-04 3H Bio. Co., Ltd. A peptide used for immunotherapeutics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08508722A (ja) * 1993-03-23 1996-09-17 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
JP2010527964A (ja) * 2007-05-24 2010-08-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
JP2013523617A (ja) * 2010-03-26 2013-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｉｖワクチン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
EP1850871A2 (en) * 2005-02-16 2007-11-07 Novartis Vaccines and Diagnostics, Inc. Adjuvant composition comprising aluminium phosphate and 3d-mpl

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08508722A (ja) * 1993-03-23 1996-09-17 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
JP2010527964A (ja) * 2007-05-24 2010-08-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
JP2013523617A (ja) * 2010-03-26 2013-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｉｖワクチン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROC.NATL.ACAD.SCI.USA, vol. 89, JPN6018014526, 1992, pages 358 - 362, ISSN: 0003946359 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020090445A (ja) * 2018-12-04 2020-06-11 国立大学法人大阪大学 免疫賦活剤
JP7385206B2 (ja) 2018-12-04 2023-11-22 国立大学法人大阪大学 免疫賦活剤

Also Published As

Publication number Publication date
RU2016141621A3 (enExample) 2018-05-11
MX2016012166A (es) 2017-03-15
US20170165358A1 (en) 2017-06-15
RU2016141621A (ru) 2018-04-25
WO2015147899A1 (en) 2015-10-01
SG11201607404PA (en) 2016-10-28
AU2014388299A1 (en) 2016-10-20
BR112016021692A2 (pt) 2017-08-15
CN106535929A (zh) 2017-03-22
EP3122379A1 (en) 2017-02-01
CA2943050A1 (en) 2015-10-01
SG10201808312YA (en) 2018-10-30
KR20170016315A (ko) 2017-02-13

Similar Documents

Publication Publication Date Title
JP6608422B2 (ja) モノホスホリルリピッドａ（ｍｐｌａ）含有リポソーム組成物およびサポニンを含む非毒性アジュバント製剤
Kersten et al. Liposomes and ISCOMS
JP3923518B2 (ja) ワクチン組成物用アジュバント
AU631377B2 (en) Affinity associated vaccine
CA2086831C (en) Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US4196191A (en) Biological preparations
US7604803B2 (en) Method to enhance an immune response of nucleic acid vaccination
JP4685005B2 (ja) アジュバントを含む機能的に再構成されたウイルス膜
AP431A (en) Influenza vaccine compositions.
US4148876A (en) Biological preparations
JP6466571B2 (ja) アジュバント添加ビロソームを提供する方法およびそれによって得られるアジュバント添加ビロソーム
JP2017515889A5 (enExample)
JPH04210925A (ja) 鼻腔内または吸入投与用ワクチン製剤およびその製造方法
US11045542B2 (en) Method of reducing reactogenicity induced by administration of vaccine or immunogenic composition
JP2017509713A (ja) アルミニウム塩に吸着させたワクチンの免疫賦活能を強化するための方法
ES2853773T3 (es) Procedimientos novedosos para inducir una respuesta inmune
CA1079634A (en) Antigens bound to exterior surface of microvesicles
US5897873A (en) Affinity associated vaccine
Arenas et al. Coincorporation of LpxL1 and PagL Mutant Lipopolysaccharides into Liposomes with Neisseria meningitidi s Opacity Protein: Influence on Endotoxic and Adjuvant Activity
JP5279497B2 (ja) 多糖抗原及びタンパク質アジュバントを含むリポソームワクチン組成物
ES2242376T3 (es) Administracion de particulas inmunogenas mediante particulas de agshb.
Glück et al. Virosomes, a new liposome-like vaccine delivery system
Kersten et al. Antigen Carriers: A Success Determining Factor for Subunit Vaccines?
Thibodeau Immunosome technology to improve antigen presentation for efficient and safe viral vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180723

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181225